TG Therapeutics financials at a glance

+ Portfolio

The revenue of TG Therapeutics is reported as 0.23366 billion Dollars in the fiscal year 2023. The earnings were 0.09 Dollars per share in 2023, which was 106.16 higher than 2022. And about -0.03141 billion Dollars are reported as free cash flow in the financials of TG Therapeutics 2023. No dividends were paid to the shareholders of the TG Therapeutics stock NasdaqCM:TGTX in the financial year 2023.

$233.66M

Revenue

$0.09

Earnings Per Share

93.95%

Gross Margin %

$40.03M

Free Cash Flow

Revenue

233.66

Earnings Per Share

0.09

Gross Margin %

93.95

Free Cash Flow

40.03

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Rev.	Revenue	N/A	$233.66M	$2.79M	$6.69M	$0.15M	$0.15M	$0.15M	$0.15M	$0.15M	$0.15M	$0.15M	$0.15M	$0.02M
GM %	Gross Margin %	96.69%	93.95%	90.48%	88.19%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
OM	Operating Margin	-9.98%	8.83%	-69.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-0.18	$0.09	$-1.46	$-2.63	$-2.42	$-1.96	$-2.30	$-1.91	$-1.60	$-1.38	$-1.64	$-0.70	$-1.17
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0.00%	-0.00%	0	0	0	0	0	0	0	0	0	0
Sha.	Shares	N/AM	144.78M	137.63M	130.79M	129.8M	102.31M	77.77M	69.22M	48.27M	46.69M	40.14M	27.34M	19.19M
OCF	Operating Cash Flow	N/A	$-31.41M	$-,176.17M	$-,295.52M	$-,214.51M	$-,133.78M	$-,128.93M	$-93.76M	$-61.59M	$-44.69M	$0.00M	$-10.82M	$0.00M
FCF	Free Cash Flow	N/A	$40.03M	$-,176.18M	$-,296.04M	$-,214.86M	$-,133.91M	$-,129.02M	$-93.77M	$-61.94M	$-44.73M	$0.00M	$-10.83M	$0.00M
FCFS	Free Cash Flow Per Share	$-0.30	$-0.22	$-1.30	$-2.24	$-1.86	$-1.50	$-1.71	$-1.51	$-1.26	$-0.98	$-1.03	$-0.42	$-0.40

TG Therapeutics financials at a glance

Financials

Discover